Tag: Bayer

Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

BiotechnologyJuly 1, 2020

TARRYTOWN, N.Y. and PARIS, July 2, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Phase 3 trial of...

Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer

BiotechnologyJuly 1, 2020

LONDON--(BUSINESS WIRE)-- Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLI), today announces that Dr Gilbert Wagener...

Newly merged Mereo BioPharma looks to OncoMed for R&D hires

BiotechnologyJune 30, 2020

Mereo BioPharma canceled its expected IPO last year in a reverse merger with OncoMed and now is filling up a number of key...

Newly merged Mereo BioPharma looks to OncoMed for R&D hires

BiotechnologyJune 30, 2020

Mereo BioPharma canceled its expected IPO last year in a reverse merger with OncoMed and now is filling up a number of key...

Apple and Disney prove reopening isn’t easy

CNNJune 25, 2020

A version of this story first appeared in CNN Business' Before the Bell newsletter. Not a subscriber? You can sign up right here.But...

Coronavirus Live Updates: Millions of Doses of Malaria Drugs in Limbo

New York TimesJune 17, 2020

Here’s what you need to know:U.S. officials don’t know what to do with 66 million doses of two malaria drugs in the federal...

Trump Hydroxychloroquine Push Secured Millions of Likely Useless Coronavirus Pills

New York TimesJune 16, 2020

WASHINGTON — The Food and Drug Administration’s abrupt decision this week to revoke an emergency waiver for two malaria drugs promoted by President...

Phishing Attack Hits German Coronavirus Task Force

Cyber SecurityJune 9, 2020

As reported by Threatpost, researchers from IBM are warning of an ongoing phishing attack that’s targeting the credentials of more than 100 high-profile executives...

AI Drug Discovery Firm Exscientia Closes €54M Series C

AIMay 29, 2020

UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its artificial intelligence (AI) technology to guide drug discovery. The...